Document is current

Article History

Received: 19 December 2023

Accepted: 28 January 2024

First Online: 12 February 2024

Declarations

:

: The study was approved by the Vall d’Hebron Ethics Committee (PR(AG)53/2017). All patients gave an informed consent for the analysis of anonymous patients’ data.

: All patients and their legal tutors consented to publication of anonymous individual data.

: CLH reports no disclosures. EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape; his salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020, Instituto de Salud Carlos III (CM20/00217). He is a junior editor for Cephalalgia. JRM reports no disclosures. VJG reports no disclosures. AA has received honoraria from Allergan-AbbVie, Novartis, Chiesi. MTF has received honoraria from Allergan-AbbVie, Novartis, Chiesi and Teva. PPR has received, in the last three years, honoraria as a consultant and speaker for: AbbVie, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; as well as, Instituto Salud Carlos III, EraNet Neuron, European Regional Development Fund (001-P-001682) under the framework of the FEDER Operative Programme for Catalunya 2014-2020 - RIS3CAT; has received funding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Novartis, Teva. She is the Honorary Secretary of the International Headache Society. She is in the editorial board of Revista de Neurologia. She is an associate editor for Cephalalgia, Headache, Neurologia, The Journal of Headache and Pain and Frontiers of Neurology. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of www.midolordecabeza.org. PPR does not own stocks from any pharmaceutical company.